We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prognostic factors for patients with advanced non-small cell lung cancer treated with gemcitabine-platinum as first-line therapy in an observational setting in China.
- Authors
Ye, Wenyu; Yang, Yicheng; Wang, Jin; Kadziola, Zbigniew; Rajan, Narayan; Qin, Shukui
- Abstract
Background This study examined the prognostic factors associated with survival in advanced non-small cell lung cancer ( NSCLC) patients receiving gemcitabine-platinum regimens as first-line therapy in real-world clinical settings in China. Methods Data was analyzed from a multinational, prospective, non-interventional, observational study of individuals receiving gemcitabine-platinum regimens as first-line therapy for NSCLC, focusing on 300 patients from mainland China. A Cox regression model was used to determine the association of 38 prognostic factors, including patient smoking characteristics, with overall survival. Results In these 300 patients, the mean age was 58.9 (±10.8) years, with males comprising 71% of the population. Thirty percent of patients had an Eastern Cooperative Oncology Group performance status ( PS) of 0 and 70% had a PS of 1. The majority of patients had NSCLC of adenocarcinoma origin (57%). Multivariate Cox regression analyses adjusted for baseline factors revealed that gender, tumor ( T) staging, metastasis ( M) staging, liver metastases, serum albumin, and superior vena cava obstruction were significant prognostic factors. Smoking during therapy was not significantly associated with survival, although numbers were small for this variable ( n = 16). Weight loss of >10% was a significant prognostic factor for adverse events. Conclusions Gender, T staging, M staging, liver metastases, superior vena cava obstruction, and serum albumin are prognostic factors affecting overall survival in mainland Chinese patients receiving first-line gemcitabine-platinum regimens for advanced NSCLC. These negative prognostic factors may warrant further investigation in clinical trials.
- Subjects
LUNG cancer treatment; CHEST tumors; ANTIMETABOLITES; CANCER chemotherapy; CANCER patients; COMBINATION drug therapy; DRUG toxicity; LONGITUDINAL method; LUNG tumors; EVALUATION of medical care; ONCOLOGY; PLATINUM; TUMOR classification; DATA analysis; DESCRIPTIVE statistics; DIAGNOSIS
- Publication
Thoracic Cancer, 2014, Vol 5, Issue 4, p319
- ISSN
1759-7706
- Publication type
Article
- DOI
10.1111/1759-7714.12095